News
TipRanks on MSN3h
Ascendis Pharma price target raised to $216 from $201 at BofABofA raised the firm’s price target on Ascendis Pharma (ASND) to $216 from $201 and keeps a Buy rating on the shares. The firm notes the company ...
Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for TransCon ® CNP (navepegritide) for the treatment of children with achondroplasia, a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback